These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29929441)

  • 1. Imipridone ONC201: combination therapy in hematologic malignancies.
    Chari A; Barlogie B
    Cell Cycle; 2018; 17(16):1947-1948. PubMed ID: 29929441
    [No Abstract]   [Full Text] [Related]  

  • 2. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
    Prabhu VV; Talekar MK; Lulla AR; Kline CLB; Zhou L; Hall J; Van den Heuvel APJ; Dicker DT; Babar J; Grupp SA; Garnett MJ; McDermott U; Benes CH; Pu JJ; Claxton DF; Khan N; Oster W; Allen JE; El-Deiry WS
    Cell Cycle; 2018; 17(4):468-478. PubMed ID: 29157092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ONC201 shows promise in AML treatment.
    Edwards H; Ge Y
    Cell Cycle; 2018; 17(3):277. PubMed ID: 29285978
    [No Abstract]   [Full Text] [Related]  

  • 4. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
    Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS
    Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.
    Ishizawa J; Kojima K; Chachad D; Ruvolo P; Ruvolo V; Jacamo RO; Borthakur G; Mu H; Zeng Z; Tabe Y; Allen JE; Wang Z; Ma W; Lee HC; Orlowski R; Sarbassov dos D; Lorenzi PL; Huang X; Neelapu SS; McDonnell T; Miranda RN; Wang M; Kantarjian H; Konopleva M; Davis RE; Andreeff M
    Sci Signal; 2016 Feb; 9(415):ra17. PubMed ID: 26884599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer.
    Lev A; Lulla AR; Ross BC; Ralff MD; Makhov PB; Dicker DT; El-Deiry WS
    Mol Cancer Res; 2018 May; 16(5):754-766. PubMed ID: 29588330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and clinical introduction of first-in-class imipridone ONC201.
    Allen JE; Kline CL; Prabhu VV; Wagner J; Ishizawa J; Madhukar N; Lev A; Baumeister M; Zhou L; Lulla A; Stogniew M; Schalop L; Benes C; Kaufman HL; Pottorf RS; Nallaganchu BR; Olson GL; Al-Mulla F; Duvic M; Wu GS; Dicker DT; Talekar MK; Lim B; Elemento O; Oster W; Bertino J; Flaherty K; Wang ML; Borthakur G; Andreeff M; Stein M; El-Deiry WS
    Oncotarget; 2016 Nov; 7(45):74380-74392. PubMed ID: 27602582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Direct Molecular Target for Imipridone ONC201 Is Finally Established.
    Wang S; Dougan DA
    Cancer Cell; 2019 May; 35(5):707-708. PubMed ID: 31085171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.
    Talekar MK; Allen JE; Dicker DT; El-Deiry WS
    Cell Cycle; 2015 Aug; 14(15):2422-8. PubMed ID: 26030065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
    Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
    J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
    Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
    Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases.
    Kline CL; Van den Heuvel AP; Allen JE; Prabhu VV; Dicker DT; El-Deiry WS
    Sci Signal; 2016 Feb; 9(415):ra18. PubMed ID: 26884600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells.
    Yuan X; Kho D; Xu J; Gajan A; Wu K; Wu GS
    Oncotarget; 2017 Mar; 8(13):21626-21638. PubMed ID: 28423492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
    Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
    Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.
    Wagner J; Kline CL; Zhou L; Campbell KS; MacFarlane AW; Olszanski AJ; Cai KQ; Hensley HH; Ross EA; Ralff MD; Zloza A; Chesson CB; Newman JH; Kaufman H; Bertino J; Stein M; El-Deiry WS
    J Clin Invest; 2018 Jun; 128(6):2325-2338. PubMed ID: 29533922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10.
    Allen JE; Prabhu VV; Talekar M; van den Heuvel AP; Lim B; Dicker DT; Fritz JL; Beck A; El-Deiry WS
    Cancer Res; 2015 Apr; 75(8):1668-74. PubMed ID: 25681273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Dopamine Receptors in the Anticancer Activity of ONC201.
    Kline CLB; Ralff MD; Lulla AR; Wagner JM; Abbosh PH; Dicker DT; Allen JE; El-Deiry WS
    Neoplasia; 2018 Jan; 20(1):80-91. PubMed ID: 29216597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR inhibition sensitizes ONC201-induced anti-colorectal cancer cell activity.
    Jin ZZ; Wang W; Fang DL; Jin YJ
    Biochem Biophys Res Commun; 2016 Sep; 478(4):1515-20. PubMed ID: 27565731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study.
    Feng Y; Zhou J; Li Z; Jiang Y; Zhou Y
    PLoS One; 2016; 11(9):e0162133. PubMed ID: 27626799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
    Ralff MD; Kline CLB; Küçükkase OC; Wagner J; Lim B; Dicker DT; Prabhu VV; Oster W; El-Deiry WS
    Mol Cancer Ther; 2017 Jul; 16(7):1290-1298. PubMed ID: 28424227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.